The HIRA is reviewing the benefit criteria for JW Pharma's hemophiliac injection Hemlibra (Emicizumab).

Currently, patients aged 1 and older and under 12 years of age may be re-administered if they fail the Immune Tolerance Induction (ITI) or if they meet the ITI target criteria (Trial 2020-164, 2020. 6.1.), or if they are unable to try, or if an antibody is re-implemented in ITI.

Therefore, patients with severe type A hemophilia under the age of 12 must receive ITI over two to three years in order to receive Hemlibra's benefits.

Some medical institutions wrote a report on pediatric patients who could not attempt ITI and asked the Heartlands for their benefits, but they di